- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01446952
Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects
April 8, 2016 updated by: H. Lee Moffitt Cancer Center and Research Institute
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Vitamin E δ-Tocotrienol Following Single Dose Administration in Healthy Subjects
This is a Phase 1, open-label, non-randomized, dose-finding, study of Vitamin E δ-Tocotrienol in subjects with resectable pancreatic tumors.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Vitamin E tocotrienols have been shown to exhibit cancer-preventive activities in preclinical studies.
Vitamin E tocotrienols are composed of α-, β-, δ-, and γ-tocotrienols.
The investigators preclinical studies indicate that δ-tocotrienol possesses the most potent antitumor activity against pancreatic cancer.
It is believed that this micronutrient may have a role in the prevention of pancreatic cancer in healthy participants who are at increased risk of developing the disease.
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The participant is ≥ 18 years old
- The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
The participant has adequate organ function as follows:
- Serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min.
- Bilirubin ≤ the institutional upper limits of normal (ULN)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to be within institutional normal range.
- Absolute neutrophil count (ANC) ≥ 1000mm³
- Platelet count ≥ 100,000/mm³
- The participant has the capability of understanding the informed consent document and has signed the informed consent document.
- Sexually active participants (male and female) must use medically acceptable methods of contraception during the course of the study.
- Female participants of childbearing potential must have a negative pregnancy test at screening.
- Able to understand and comply with the requirements of the protocol.
Exclusion Criteria:
- The participant is receiving investigational therapy (other than the investigational therapy under study).
- The participant has received investigational therapy within 30 days prior to first dose of study drug.
- Patients who are unable to swallow capsules.
- Patients with prior malignancies, other than squamous or basal cell carcinomas, unless disease free for ≥ 5 years.
- The participant has had prior major surgery within 30 days prior to first dose of study drug.
- The participant has active infection or fever >38.5C within 3 days prior to first dose of study drug.
- The participant has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- The participant is unable or unwilling to stop taking vitamins, herbal remedies, or nonprescription medications.
- The participant is pregnant or breastfeeding.
- The participant is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation
Vitamin E δ-Tocotrienol will be administered orally as a single agent once.
Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules.
|
The first cohort will be dosed with δ-tocotrienol at 200 mg.
A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events
Time Frame: 3 weeks per participant
|
The primary objective of this study is to evaluate the safety and tolerability of Vitamin E δ-Tocotrienol and to determine the minimally effective dose (MED) or maximum tolerated dose (MTD) of Vitamin E δ-Tocotrienol administered once.
Safety will be assessed by standard clinical findings and laboratory tests.
Toxicity grade is defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)v.4.0.
Ninety-five percent confidence intervals may be calculated for selected safety and exploratory variables.
|
3 weeks per participant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Pharmacokinetic (PK) Markers of Vitamin E δ-Tocotrienol
Time Frame: 3 weeks per participant
|
Pharmacokinetic (PK) markers of Vitamin E δ-Tocotrienol in the plasma, urine, and neoplastic tissue of participants with pancreatic neoplasia.
To determine the effects of dose on the plasma pharmacokinetic (PK) of Vitamin E δ-Tocotrienol when orally administered as a single dose in healthy subjects.
Ninety-five percent confidence intervals may be calculated for selected safety and exploratory variables.
Dose escalation will be based on safety and available PK data.
|
3 weeks per participant
|
Number of Participants With Pharmacodynamic (PD) Markers of Vitamin E δ-Tocotrienol
Time Frame: 3 weeks per participant
|
Pharmacodynamic (PD) Markers of Vitamin E δ-Tocotrienol in the plasma, urine, and neoplastic tissue of participants with pancreatic neoplasia.
To evaluate pharmacodynamic (PD) markers of Vitamin E δ-Tocotrienol activity in peripheral blood.
Ninety-five percent confidence intervals may be calculated for selected safety and exploratory variables.
Correlative analysis of PD data will be done.
|
3 weeks per participant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Actual)
September 1, 2012
Study Completion (Actual)
April 1, 2016
Study Registration Dates
First Submitted
September 28, 2011
First Submitted That Met QC Criteria
October 4, 2011
First Posted (Estimate)
October 5, 2011
Study Record Updates
Last Update Posted (Estimate)
April 11, 2016
Last Update Submitted That Met QC Criteria
April 8, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCC-16152
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
Clinical Trials on Vitamin E δ-Tocotrienol
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI); BioGene Life ScienceCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)CompletedPancreatic NeoplasmsUnited States
-
Chandan K SenTerminated
-
Hadassah Medical OrganizationCompleted
-
Malaysia Palm Oil BoardUniversity of MalayaCompleted
-
National University of MalaysiaCompleted
-
Wayne State UniversityUniversiti Putra Malaysia; National Kidney Foundation; Ministry of Health, Malaysia and other collaboratorsCompletedEnd Stage Renal Disease | Chronic Kidney DiseaseUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Completed
-
Texas Tech University Health Sciences CenterWithdrawnPostmenopausal Women | DynapeniaUnited States
-
Malaysia Palm Oil BoardUniversity of MalayaCompleted